Mili

Quick links to important sections

Mili

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mili

What is Mili? (Ethinyl Estradiol and Norgestimate)

Property Description
Active ingredient Ethinyl Estradiol and Norgestimate
Form Oral tablets (combination formulation)
Pharmacological class Combined Hormonal Contraceptive (CHC)
Common use Pregnancy prevention (Systemic Contraception)
Origin Synthetic compound

Definition and Pharmacological Class

Mili is defined as a Combined Hormonal Contraceptive (CHC), which is its official pharmacological class. This prescription-only drug is a combination product designed for systemic administration to achieve endocrine regulation for pregnancy prevention. As a CHC, it differs fundamentally from progestin-only contraceptives (often known as "mini-pills") by using two distinct hormone classes to achieve a more robust and predictable method of systemic contraception. The mechanism is clinically recognized for suppressing the hormonal signals necessary for ovulation, supporting its efficacy.


Composition and Formulation

Mili consists of two active ingredients: Ethinyl Estradiol, a synthetic estrogen component, and Norgestimate, a synthetic progestin component. Both substances are classified as synthetic compounds developed for use in hormone therapy. The product is manufactured as small oral tablets presented in a solid tablet formulation suitable for daily consumption via the oral route of administration. The formulation is typically a biphasic or triphasic regimen (a variable-dose combination therapy), meaning the daily amount of Norgestimate varies across the active tablets in the cycle. This specific composition, featuring a third-generation synthetic progestin, is a differentiating factor, as pharmacological studies confirm that the choice of progestin affects the overall endocrine profile.


Primary Purpose

The primary purpose of Mili is reliable pregnancy prevention achieved through the controlled modulation of the female reproductive cycle. This combination formulation provides effective hormone regulation by executing simultaneous physiological effects, including the inhibition of ovulation and alteration of cervical fluid. A typical scenario for its use involves reproductive-age women seeking a consistent, planned method of birth control. The medication offers a primary biological block to conception by suppressing the natural hormonal fluctuations necessary for fertility, offering patients a consistent method of contraception.

Regulatory References

  1. MedlinePlus
  2. NIH DailyMed

What side effects are possible with Mili?

Possible Side Effects and Safety Information

Warning: Risk of Serious Cardiovascular Events The use of combined oral contraceptives like Mili is associated with an increased risk of serious cardiovascular events, including venous thromboembolism (VTE), myocardial infarction (heart attack), and stroke. This risk is significantly elevated in women over 35 who smoke cigarettes, and is highest during the first year of use or when restarting the medication after a break of four weeks or more.


Adverse Reactions

Adverse reactions reported in clinical data are categorized by frequency:

  • Very Common (ge 10%): Headache/migraine, nausea, vomiting, and gastrointestinal disorder.
  • Common (1% to 10%): Vaginal and urinary tract infections, breast tenderness/pain/discharge, menstrual disorders (including amenorrhea), abdominal pain, flatulence, dizziness, weight fluctuation, fluid retention, depression, mood altered, and acne.

Serious and Clinically Significant Safety Concerns

Serious reactions documented in official regulatory labeling include:

  • Thromboembolic Events: Deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction.
  • Hepatic Issues: Liver tumors (benign and malignant, such as hepatocellular carcinoma) and gallbladder disease. Discontinuation is required if jaundice (yellowing of the skin/eyes) occurs.
  • Other Risks: Hypertension (high blood pressure) and adverse changes in carbohydrate and lipid metabolism requiring monitoring.

Safety Restrictions and Contraindications

Mili is contraindicated and must not be used by women with:

  • A high risk of arterial or venous thrombotic diseases (e.g., history of DVT/PE, stroke, or severe migraines with aura).
  • Known or suspected breast cancer, liver tumors, or liver disease (e.g., acute viral hepatitis, decompensated cirrhosis).
  • Undiagnosed abnormal genital bleeding.

Use must be discontinued at least four weeks before and for two weeks after major surgery or during prolonged immobilization.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Mili (Ethinyl Estradiol and Norgestimate) establishes a precise and limited profile for potential overdosage. Overdosage of this combination hormonal contraceptive is formally documented to result in specific, non-life-threatening clinical manifestations. Regulatory authorities state that overdosage may present with nausea and the occurrence of withdrawal bleeding in females.


Severity, Exposure, and Emergency Response

The regulatory profile indicates a low-risk severity. Authorities state explicitly that there have been no reports of serious ill effects resulting from overdosage of this product. This finding is reinforced by the inclusion of data on accidental exposures, stating that overdosage involving ingestion by children has also resulted in no documented serious adverse outcomes.

Due to the lack of documented serious effects, the regulatory labels do not mandate explicit, immediate emergency actions or specific procedural instructions, such as the use of an antidote or urgent hospital monitoring. Consequently, there is no explicit, regulator-defined trigger provided in the official Overdosage section for when to seek immediate medical help. The overall management of overdosage is defined as symptomatic and supportive, strictly based on the presented manifestations. The information adheres to the descriptive data found in government-authorized prescribing texts.

Therapeutic Uses of Mili

Mili: Main Uses and Benefits

Quick Facts

  • Primary Therapeutic Use: Prevention of pregnancy.
  • Additional Supported Use: Management of moderate acne vulgaris.
  • Regulation of Cycles: May contribute to more predictable menstrual cycles.

Mili is a prescription medication utilized by females of reproductive potential to support the prevention of pregnancy. This oral treatment is an established method for contraception when used as directed.

Furthermore, this medication is a suitable therapeutic option for the management of moderate acne vulgaris in individuals who have reached menarche and wish to use an oral contraceptive for pregnancy prevention.

Use of this medication may contribute to the establishment of more regular menstrual periods and may be associated with reduced menstrual blood loss in some users.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Mili — Official Regulatory Information

Mili (Ethinyl Estradiol and Norgestimate) is a Combined Hormonal Contraceptive (CHC) indicated only for females of reproductive potential for pregnancy prevention, or for moderate acne in females who have achieved menarche and desire oral contraception. Regulatory documents establish numerous absolute contraindications that strictly prohibit use in certain populations.


Eligibility Classification Official Regulatory Status
Populations Contraindicated Women over 35 years old who smoke; individuals with a current or history of thrombotic disorders (e.g., DVT, stroke); a history of breast cancer or other hormone-sensitive tumors; liver tumors or severe liver disease; uncontrolled hypertension; diabetes with vascular disease; or migraine headaches with aura.
Age-Related Rules Not indicated for use before menarche or in postmenopausal women.
Physiological Status Contraindicated during known or suspected pregnancy. Not recommended while breastfeeding, as it may decrease milk production.
Eligibility Restrictions Use is restricted for at least four weeks after delivery in non-breastfeeding women and must be temporarily stopped before and through two weeks after major surgery due to heightened thromboembolism risk. The drug must be discontinued if jaundice develops.

Connection to the Overall Eligibility Profile

Regulatory authorities define eligibility primarily by assessing a patient's risk for serious cardiovascular events and the presence of hormone-sensitive conditions, classifying these risks as absolute contraindications. The official label requires users to be within the reproductive age range and strictly limits use during the postpartum and peri-operative periods, focusing the drug's use on the documented eligible population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation defines the interaction profile of Mili primarily through pharmacokinetic effects that alter the exposure of its hormonal components. Co-administration is formally contraindicated with specific combination regimens for Hepatitis C Virus (HCV) that contain Ombitasvir, Paritaprevir, and Ritonavir, with or without Dasabuvir.


The most common class of interaction involves enzyme-mediated exposure modification via the Cytochrome P450 3A4 (CYP3A4) pathway. This results in two key official patterns:

Substance Category Official Effect on Contraceptive Hormone Exposure
CYP3A4 Inducers (e.g., rifampicin, phenytoin) Decreases plasma concentrations, potentially diminishing effectiveness.
CYP3A4 Inhibitors (e.g., fluconazole, grapefruit juice) Increases plasma hormone concentrations.

Other agents are documented to modify hormone exposure or clearance. For instance, atorvastatin or rosuvastatin increase the AUC of Ethinyl Estradiol. The bile acid sequestrant Colesevelam significantly decreases Ethinyl Estradiol exposure, a pharmacokinetic effect that is officially managed by requiring the two products to be administered at least 4 hours apart. Interactions are also documented with the herbal product St. John's wort and the food product grapefruit juice.

Mechanism of Action

How Mili Works

Mili is a fully human monoclonal antibody (IgG2). Its mechanism is characterized by selective inhibition of the Receptor Activator of NF-kappaB Ligand (RANKL). Mili binds to RANKL, preventing this ligand from interacting with its receptor, Receptor Activator of NF-kappaB (RANK), which is expressed on the surface of pre-osteoclasts and mature osteoclasts.

This molecular blockade effectively inhibits the signal transduction cascade necessary for the terminal differentiation, functional activity, and long-term survival of osteoclasts—the cells responsible for bone resorption. The resulting decrease in osteoclastogenesis and activity modulates the overall rate of bone remodeling. This system-level physiological effect shifts the equilibrium between bone formation and resorption, favoring a reduction in bone resorption activity.

Dosage and Administration Information

Official Administration Guidelines

Mili (norgestimate and ethinyl estradiol) is designed for oral administration as part of a fixed, cyclic regimen to ensure continuous hormone management. The medication is taken daily following a standardized sequence.

Standard Dosing Protocol

Feature Guideline
Dose and Route One tablet taken orally once daily.
Regimen Structure 28-day cycle consisting of 21 consecutive days of active hormone tablets, followed immediately by 7 days of hormone-free (inactive) tablets.
Timing Must be taken at the same time each day for the entire 28-day course to maintain consistent hormone levels. The tablet may be taken with or without food.

The effectiveness of this combined hormonal contraceptive is dependent upon strict adherence to the pill sequence found in the blister pack. The dosing is non-adjustable; the same daily schedule applies when used for contraception or the management of moderate acne vulgaris in appropriate female patients.

Specific Use Requirements

When initiating the regimen, patients may use a Day 1 Start (first pill on the first day of menstruation) or a Sunday Start. If the latter method is chosen, a non-hormonal back-up contraceptive is typically required for the first seven days of the initial cycle.

If an active tablet is missed by more than 12 hours, contraceptive protection may be compromised. In such instances, clinical protocols advise immediate action and the use of a back-up non-hormonal method for the subsequent seven consecutive days of active tablet use. Specific rules also apply to initiation in women who are four or more weeks postpartum but are not breastfeeding.

Recent Clinical Evidence

Research evidence / Overview of studies for Mili


Evidence for Use in Pregnancy Prevention

Mili was studied for the prevention of pregnancy in research primarily conducted through Pivotal Phase 3 Clinical Trials and large-scale Post-marketing Observational Studies. The research was evaluated in healthy, reproductive-aged females who were monitored for outcomes related to systemic contraception. Researchers monitored changes related to outcomes reflecting daily functioning or activity level, specifically focusing on the number of unintended pregnancies.

Findings describe patterns observed in the studies related to the Pearl Index (PI), a key outcome measure. Research describes that the PI is calculated by monitoring the rate of pregnancies per 100 women over one year of exposure in the study setting. Data show patterns related to two main measurements: the PI for "perfect use" (when the medicine is taken exactly as prescribed in the study) and the PI for "typical use" (which includes instances of imperfect use in a real-world setting).

Comparative evidence is lacking when reviewing this specific Mili formulation against every other available combined hormonal contraceptive. Also, research provides context but not individual predictions, as results apply only to the groups studied.


Evidence for Use in Managing Moderate Acne Vulgaris

The evidence base for Mili's use in managing acne primarily stems from Randomized, Double-Blind, Placebo-Controlled Trials (RCTs). This type of research was applied in studies examining post-menarcheal females diagnosed with moderate acne vulgaris who also desired an oral contraceptive. The research examined outcomes linked to inflammatory or irritative states, such as changes in the number of acne lesions (including inflammatory and total lesions) and an overall assessment of skin condition by an investigator.

Studies monitored how these outcomes evolved over defined time intervals. Findings describe patterns observed in the studies where the group receiving the medication showed different changes in lesion counts compared to the placebo group over the study period.

Follow-up durations were limited in the controlled trials for acne, typically lasting six menstrual cycles (approximately six months). There is limited information for long-term outcomes related to the maintenance of the outcomes related to physical discomfort (acne) after the initial six months.


Long-Term Research and Study Duration

The evidence base for Mili is characterized by having a documented body of intermediate-term data related to the outcomes related to systemic or functional imbalance in pregnancy prevention, as most pivotal trials observe responses over defined time intervals of up to a year. However, long-term outcomes are not fully established; evidence remains limited and heterogeneous across the same highly controlled trial structures.


Areas of Research Uncertainty and Study Limitations

The current evidence landscape highlights several limitations and areas where certainty remains low. One major limitation is the difference in measured effectiveness between perfect use and typical use of the medicine for contraception. The evidence base contributes to understanding symptom patterns but does not fully establish the long-term outcomes of the reported effects.

Key Studies & References

  1. Drug Information Portal: Norgestimate and Ethinyl Estradiol - U.S. National Library of Medicine (MedlinePlus)
  2. DailyMed: Norgestimate and Ethinyl Estradiol Tablets - Labeling Information (NIH)

Frequently Asked Questions (FAQ)

Common questions about Mili (FAQ)


Q: Are there any specific vitamins or supplements that shouldn't be taken with Mili?

A: Official regulatory documents state that Mili can interact with certain substances. Herbal products, such as St. John's wort, and some vitamins or other supplements may affect how the medicine works. Information regarding all supplements and medications is necessary for a healthcare provider to assess potential risks.


Q: Is Mili a medication that I will need to take long-term?

A: Mili is indicated for conditions like contraception and acne, which often require continuous management. The duration of therapy is a determination made by a healthcare provider based on the condition being addressed and individual patient factors. The medication is designed for long-term, cyclic use.


Q: Is Mili safe for use by older adults or seniors?

A: The official product information states that Mili is not intended for use in older adults. Specifically, it is not indicated for women who have reached menopause.


Q: What should I do if a side effect from Mili seems unusual or severe?

A: Regulatory documents advise that a serious adverse reaction requires attention. This includes signs of a blood clot (like sudden severe headache or leg pain), liver issues (like jaundice, or yellowing of the skin/eyes), or changes in vision. The regulatory information indicates that a healthcare provider should be contacted promptly if any of these serious symptoms appear.


Q: Is Mili the kind of drug that requires regular follow-up appointments?

A: Regulatory documents describe the need for routine monitoring by a healthcare provider while using Mili. This monitoring is important to check blood pressure and assess for any changes in carbohydrate or lipid metabolism (how your body processes sugar and fats).


Q: Is Mili ever used in combination with other medications?

A: Mili may be taken alongside other prescription medicines, and this is common in practice. Official information highlights the need to assess all other medicines for potential drug interactions, as some combinations may affect how well Mili works or may require careful monitoring.


Q: Is Mili considered a high-risk medication?

A: Regulatory documentation includes a serious Boxed Warning regarding the increased risk of certain cardiovascular events. These include life-threatening issues such as blood clots, heart attack, and stroke. This is a standard warning provided for this class of medicine.


Q: What are the specific ingredients in the Mili tablet/capsule?

A: Each active tablet contains the two hormones: norgestimate and ethinyl estradiol. The tablets also contain several inactive ingredients (substances used to form the pill) that may vary slightly between brand and generic versions.


Q: Does Mili have different effects on people with pre-existing kidney or liver conditions?

A: According to official sources, Mili should not be used by women who have liver tumors or known liver disease. The regulatory information does not list pre-existing kidney conditions as a general contraindication for use.


Q: Is it true that Mili should not be used by people with certain allergies?

A: The official prescribing information lists specific serious allergic reactions that have been reported, such as angioedema (severe swelling of the face, tongue, or throat). History of severe allergy or hypersensitivity to the components of the medicine is an important factor to discuss with a healthcare provider.


Q: Do the side effects of Mili usually go away over time?

A: Studies indicate that some common side effects, such as irregular uterine bleeding or spotting, often lessen or disappear after the first few months as the body adjusts to the hormonal components. The duration of other reported side effects is not explicitly detailed in the official information.


Q: Does Mili interact negatively with common over-the-counter pain relievers?

A: The hormonal component of this medicine may interact with certain common over-the-counter pain relievers, including acetaminophen and ibuprofen. This interaction may require monitoring.


Q: How long does it typically take before Mili starts to work?

A: To ensure protection against pregnancy, official guidelines state that a back-up non-hormonal method should typically be used for the first seven days when starting the regimen.


Q: What happens if I stop taking Mili suddenly?

A: Official regulatory guidance states that the discontinuation of the medicine should occur after consultation with a healthcare provider. Stopping the medicine is specifically required before major surgery or immediately if a serious symptom, like jaundice (yellowing of the skin/eyes), develops.


Q: What is known about using Mili during pregnancy or while breastfeeding?

A: According to the official regulatory label, Mili is contraindicated (should not be used) during a known pregnancy. Use while breastfeeding is described as generally not recommended because the hormones may be excreted in human milk and could potentially decrease milk production.


Q: Does taking Mili affect the results of any common lab tests?

A: Yes, official sources indicate that oral contraceptives like Mili can influence the results of certain laboratory tests. This may include changes in results related to blood clotting factors or thyroid-binding globulin levels.


Q: Is Mili a controlled substance?

A: No, Mili is not classified as a controlled substance by the US Drug Enforcement Administration (DEA).


Q: Why do some people refer to Mili by a different name?

A: Mili is a specific brand name for a medicine containing the hormones norgestimate and ethinyl estradiol. This combination of hormones may be sold under several other different brand or generic names.


Q: What is the difference between the brand name version and the generic version of Mili?

A: Generic versions contain the exact same active ingredients and are required by regulatory bodies to be bioequivalent (work the same way). The main difference is that generics may use different inactive ingredients, such as coloring or binding agents, than the brand name.


Q: Does Mili have a risk of dependence or addiction?

A: Based on regulatory classification, Mili is not a scheduled controlled substance. It is a hormonal product and is not generally associated with dependence or addiction.


Q: What happens if I accidentally take two doses of Mili?

A: The official product information states that taking more than the prescribed dose may result in symptoms such as nausea and vaginal bleeding.


Q: What types of allergic reactions are associated with Mili?

A: Serious allergic reactions have been reported in the post-marketing setting. These include angioedema (severe swelling of the face, tongue, or throat), hives (urticaria), and rash.


Q: Can Mili affect my ability to drive or operate machinery?

A: The regulatory label lists dizziness as a potential common side effect. A person experiencing dizziness, which is listed as a side effect, should exercise caution regarding driving or operating complex machinery.


Q: Is Mili available over the counter, or is a prescription always needed?

A: Mili is classified as a prescription-only medication. It is not available for purchase over the counter.


Q: How is Mili eliminated from the body?

A: The hormonal components of Mili are broken down, or metabolized, in the liver. They are then eliminated from the body primarily through both urine and feces.


Q: Can Mili cause temporary vision changes?

A: Yes, the prescribing information advises contacting a healthcare provider immediately if vision changes occur. These changes may include symptoms like blurred vision, difficulty reading, or contact lens intolerance.


Q: What is the process for switching from a different drug to Mili?

A: Official regulatory instructions for beginning Mili vary depending on the previous contraceptive method used. The specific regulatory instructions depend on the previous contraceptive method used, such as whether it was an oral pill, patch, ring, or injection.

How should Mili be stored and disposed of?

Mili tablets must be stored at Controlled Room Temperature, which is defined by regulators as 20 C to 25 C (68 F to 77 F). The product is permitted to experience brief temperature excursions between 15 C and 30 C (59 F and 86 F).

The medication must be kept in the original blister pack and stored away from light. To ensure child safety, Mili and all medicines must be stored out of the sight and reach of children.

Disposal must adhere to local regulations and official guidance for unused pharmaceuticals. Mili is not on the U.S. FDA's flush list. Unused or expired tablets should be disposed of primarily through a drug take-back program. If a take-back option is unavailable, discard the tablets in household trash after mixing them with an undesirable substance, such as dirt or used coffee grounds, and sealing the mixture in a bag or container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mili found in:

A-Z Index: